A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer

作者：Stinchcombe Thomas E^*; Bradford Daniel S; Hensing Thomas A; LaRocca Renato V; Saleh Mansoor; Evans Tracey; Bakri Kamal; Socinski Mark A

来源：Cancer Investigation, 2010, 28(2): 208-215.

DOI：10.3109/07357900903286958

• Platinum-based
• Clinical trial
• Lung cancer
• Epidermal growth factor receptor (EGFR)
• First-line therapy

Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase 11 trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

• 出版日期2010-2